Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Autor: Evan Y. Yu, Michael P. Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep M. Piulats, Leonard J. Appleman, Emanuela Romano, Gwenaelle Gravis, Howard Gurney, Martin Bögemann, Urban Emmenegger, Anthony M. Joshua, Mark Linch, Srikala Sridhar, Henry J. Conter, Brigitte Laguerre, Christophe Massard, Xin Tong Li, Charles Schloss, Christian H. Poehlein, Johann S. de Bono

Publikováno v: European Urology. 82:22-30

Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enzalutamide and need more efficacious treatments.To evaluate the efficacy and safety of pembrolizumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa4643d037afae5e03bf2fb4cc807f9
https://doi.org/10.1016/j.eururo.2022.02.023

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Autor: Johann de Bono, Christian Poehlein, Allison Allen, Carrie A. Adelman, Jinyu Kang, Julia A. Elvin, Robert Huisden, Alexander Kohlmann, Charles Padua, Young Deuk Choi, Craig Gedye, Nobuaki Matsubara, Mustafa Özgüroǧlu, Guilhem Roubaud, Michael P. Kolinsky, Niven Mehra, David Olmos, Joaquin Mateo, Shahneen Sandhu, Neal Shore, Fred Saad, Karim Fizazi, Caroline Sibilla, Claire Corcoran, Maha Hussain

Purpose:Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and future molecularly targeted therapies.Patients and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af4a5f059d9d09c98a4b55d79bc2c7e
https://doi.org/10.1158/1078-0432.c.6532301

Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer

Autor: Cora N, Sternberg, Karim, Fizazi, Fred, Saad, Neal D, Shore, Ugo, De Giorgi, David F, Penson, Ubirajara, Ferreira, Eleni, Efstathiou, Katarzyna, Madziarska, Michael P, Kolinsky, Daniel I G, Cubero, Bettina, Noerby, Fabian, Zohren, Xun, Lin, Katharina, Modelska, Jennifer, Sugg, Joyce, Steinberg, Maha, Hussain, R, Waterhouse

Publikováno v: Sternberg, C N, Fizazi, K, Saad, F, Shore, N D, de Giorgi, U, Penson, D F, Ferreira, U, Efstathiou, E, Madziarska, K, Kolinsky, M P, Cubero, D I G, Noerby, B, Zohren, F, Lin, X, Modelska, K, Sugg, J, Steinberg, J, Hussain, M & The PROSPER Investigators 2020, ' Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer ', New England Journal of Medicine, vol. 382, no. 23, pp. 2197-2206 . https://doi.org/10.1056/NEJMoa2003892
New England Journal of Medicine, 382(23), 2197-2206. MASSACHUSETTS MEDICAL SOC

Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada3068f332332d3148bedbc332995e5
https://research.rug.nl/en/publications/55cc0758-3a20-4830-a0d2-94595129fd5f

Corrigendum to 'Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study' [Eur Urol 83 (2023) 15–26]

Autor: Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C.C. Fong, Tilman Todenhöfer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono

Publikováno v: European Urology. 83:e87

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::274305b378d05dc3bb09dace5d1a86b3
https://doi.org/10.1016/j.eururo.2022.11.025

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer

Autor: Pasquale, Rescigno, David, Lorente, Diletta, Bianchini, Roberta, Ferraldeschi, Michael P, Kolinsky, Spyridon, Sideris, Zafeiris, Zafeiriou, Semini, Sumanasuriya, Alan D, Smith, Niven, Mehra, Anuradha, Jayaram, Raquel, Perez-Lopez, Joaquin, Mateo, Chris, Parker, David P, Dearnaley, Nina, Tunariu, Alison, Reid, Gerhardt, Attard, Johann S, de Bono

Publikováno v: European urology. 70(5)

The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a60adb8851da183cc3ae8e080c42344e
https://pubmed.ncbi.nlm.nih.gov/27321503